Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has received a consensus recommendation of “Buy” from the sixteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $21.18.
Several brokerages have recently commented on ALDR. BidaskClub raised shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Svb Leerink began coverage on shares of Alder Biopharmaceuticals in a research report on Tuesday, May 28th. They set an “outperform” rating on the stock. Leerink Swann began coverage on shares of Alder Biopharmaceuticals in a research report on Tuesday, May 28th. They set an “outperform” rating and a $21.00 price target on the stock. Zacks Investment Research lowered shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Finally, Cowen set a $18.00 price target on shares of Alder Biopharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 3rd.
In related news, EVP James B. Bucher sold 1,897 shares of the stock in a transaction that occurred on Thursday, April 25th. The shares were sold at an average price of $13.85, for a total transaction of $26,273.45. Following the sale, the executive vice president now owns 11,706 shares in the company, valued at approximately $162,128.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 17.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Samlyn Capital LLC boosted its position in Alder Biopharmaceuticals by 47.2% in the fourth quarter. Samlyn Capital LLC now owns 2,818,788 shares of the biopharmaceutical company’s stock valued at $28,892,000 after buying an additional 904,098 shares in the last quarter. BB Biotech AG boosted its position in Alder Biopharmaceuticals by 22.1% in the fourth quarter. BB Biotech AG now owns 2,766,008 shares of the biopharmaceutical company’s stock valued at $28,352,000 after buying an additional 500,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Alder Biopharmaceuticals by 22.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock valued at $11,910,000 after buying an additional 215,098 shares in the last quarter. Bellevue Group AG boosted its position in Alder Biopharmaceuticals by 24.1% in the fourth quarter. Bellevue Group AG now owns 1,123,813 shares of the biopharmaceutical company’s stock valued at $11,519,000 after buying an additional 218,559 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Alder Biopharmaceuticals by 33.9% in the first quarter. Geode Capital Management LLC now owns 868,135 shares of the biopharmaceutical company’s stock valued at $11,850,000 after buying an additional 219,695 shares in the last quarter.
Shares of ALDR traded up $0.32 during mid-day trading on Friday, hitting $12.17. 29,703 shares of the company’s stock were exchanged, compared to its average volume of 722,873. Alder Biopharmaceuticals has a 52 week low of $9.44 and a 52 week high of $20.87. The stock has a market capitalization of $959.46 million, a PE ratio of -2.49 and a beta of 2.78. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 1.21.
Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by ($0.47). Equities research analysts predict that Alder Biopharmaceuticals will post -4.43 earnings per share for the current fiscal year.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Recommended Story: What are the reasons investors use put options?
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.